Financials

  • Market Capitalization 209.2 M
  • Employee 87
  • Founded 2015
  • CEO N/A
  • Website www.kerostx.com
  • Headquarter Massachusetts, United States
  • FIGI BBG00H1HP9G9
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
8.85
Relación precio/flujo de caja
3.16

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
3592
AGEN
Agenus Inc. - Common Stock
5.08 USD-16.99%+47.25%+55.83%-19.11%211.54 M USD
3595
SLGL
Sol-Gel Technologies Ltd. - Ordinary Shares
75.39 USD+2.00%-4.57%+3.26%+843.55%210.05 M USD
3601
OTLK
Outlook Therapeutics, Inc. - Common Stock
1.73 USD+11.61%+21.83%+45.38%+319.39%209.09 M USD
3602
RNA
Atrium Therapeutics, Inc. - Common Stock
12.22 USD0.00%-6.50%-4.16%-82.62%209.03 M USD

Noticias